News

Anti-Ebola drug gives fresh hope for coronavirus treatment

April 11, 2020 05:49 PM


An antiviral drug developed in the fight against ebola has shown promising first signs it could be used to treat coronavirus following a small trial, reported Daily Mail.

More than half of a group of severely ill COVID-19 patients improved after receiving Gilead's experimental drug remdesivir, doctors reported.

However, there is no way to know the odds of the drug's effectiveness because there was no comparison group in the trial of 53 people. The results published by the New England Journal of Medicine are the first in Covid-19 patients for remdesivir.

The Gilead Sciences drug has shown promise against other coronaviruses in the past and in lab tests against the one causing the current pandemic, which now has claimed more than 100,000 lives. At least five large studies are testing remdesivir, and the company also has given it to more than 1,700 patients on a case-by-case emergency basis.

Friday's results are on 53 of those patients, ages 23 to 82, admitted to hospital in the United States, Europe, Canada and Japan. Thirty-four of them were sick enough to require breathing machines.

All were given the drug through an IV for 10 days or as long as they tolerated it. After 18 days on average, 36 patients, or 68%, needed less oxygen or breathing machine support. Eight others worsened.

Seven patients died, nearly all of them over age 70. That 13% mortality rate is lower than seen in some other reports, but no true comparisons can be made without a study rigorously testing the drug in similar groups of patients, the authors noted.

A dozen patients had serious problems but it was not clear whether they were from the drug or their disease. Those included septic shock and trouble with kidneys and other organs. Four discontinued treatment because of health problems they developed.

“It looks encouraging,” said Dr Elizabeth Hohmann, an infectious disease specialist at Massachusetts General Hospital who is helping lead one of the studies testing the drug. The problems that occurred were not unexpected given the disease, she said.

Dr Derek Angus, critical care chief at the University of Pittsburgh Medical Centre who was not involved with the research, said the recovery rate is good but 'there is no way of knowing from this series if remdesivir was helpful'.

Results from more rigorous studies are expected by the end of this month.



Most Read

  1. Yet another burden on people: Govt hikes oil prices Yet another burden on people: Govt hikes oil prices
  2. Nadeem Mahboob named federal health secretary Nadeem Mahboob named federal health secretary
  3. Public reacts to Bohemia's music video ‘Salsa’ starring Sistrology Public reacts to Bohemia's music video ‘Salsa’ starring Sistrology
  4. Palestinian Embassy denounces fake news of orphan adoption in Pakistan Palestinian Embassy denounces fake news of orphan adoption in Pakistan
  5. Saudis offered PIA, airports, joint ventures to build five-star hotels Saudis offered PIA, airports, joint ventures to build five-star hotels
  6. Team formed to probe woman’s death after tortured by cop on train Team formed to probe woman’s death after tortured by cop on train

Opinion

  1. Insights into the Pakistan Stock Exchange's Recent Record High Triumph
    Insights into the Pakistan Stock Exchange's Recent Record High Triumph

    By Zulfiqar Ali Mir

  2. IMEC to sabotage CPEC
    IMEC to sabotage CPEC

    By Dr Asif Channer

  3. 1947 TO FORM 47
    1947 TO FORM 47

    By Dr Asif Channer

  4. Beijing wants to further highlight industrial sector in its country and take scientific innovation to new heights....
    Beijing wants to further highlight industrial sector in its country and take scientific innovation to new heights....

    By Ali Ramay

  5. Global race: China will reduce its unnecessary expenses
    Global race: China will reduce its unnecessary expenses

    By Ali Ramay

  6. Channer Pir: The Great Saint of Cholistan
    Channer Pir: The Great Saint of Cholistan

    By Dr Asif Channer